Patents by Inventor Norikazu Otake
Norikazu Otake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11198690Abstract: Provided is a novel process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative. More specifically, provided is a process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1): the process comprising reacting 3-aminopropan-1-ol with glyoxylic acid.Type: GrantFiled: July 11, 2018Date of Patent: December 14, 2021Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takaaki Matsubara, Hiroki Urabe, Ryo Suzuki, Aya Futamura, Ryo Kinoshita, Nobutaka Hattori, Hideaki Tabuse, Koreaki Imura, Norikazu Otake
-
Publication number: 20210147400Abstract: Provided is a novel process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative. More specifically, provided is a process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1): the process comprising reacting 3-aminopropan-1-ol with glyoxylic acid.Type: ApplicationFiled: July 11, 2018Publication date: May 20, 2021Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takaaki MATSUBARA, Hiroki URABE, Ryo SUZUKI, Aya FUTAMURA, Ryo KINOSHITA, Nobutaka HATTORI, Hideaki TABUSE, Koreaki IMURA, Norikazu OTAKE
-
Publication number: 20210070747Abstract: Provided are: useful novel compounds that exhibit antibacterial activity based on their actions for inhibiting GyrB of DNA gyrase and ParE of topoisomerase IV; and 2(1H)-quinolinone derivatives represented by formula [1]: or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 23, 2018Publication date: March 11, 2021Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Hideaki AMADA, Norikazu OTAKE, Fumihito USHIYAMA, Chunhae KIM, Tomoki TAKEUCHI, Nozomi TANAKA
-
Patent number: 10689327Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.Type: GrantFiled: July 15, 2019Date of Patent: June 23, 2020Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Norikazu Otake, Takashi Hashihayata, Yohei Matsuda, Seiji Masuda, Yuko Yamauchi
-
Publication number: 20190337887Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.Type: ApplicationFiled: July 15, 2019Publication date: November 7, 2019Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Norikazu OTAKE, Takashi HASHIHAYATA, Yohei MATSUDA, Seiji MASUDA, Yuko YAMAUCHI
-
Patent number: 10464884Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.Type: GrantFiled: April 18, 2017Date of Patent: November 5, 2019Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Norikazu Otake, Takashi Hashihayata, Yohei Matsuda, Seiji Masuda, Yuko Yamauchi
-
Patent number: 10207976Abstract: A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 29, 2016Date of Patent: February 19, 2019Assignee: TAISHO PHARMACEUTICAL CO., LTDInventors: Norikazu Otake, Daisuke Matsuda, Rie Shimono, Hideaki Tabuse, Minoru Moriya, Yohei Kobashi, Yohei Matsuda, Tomokazu Tamaoki
-
Publication number: 20190047943Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.Type: ApplicationFiled: April 18, 2017Publication date: February 14, 2019Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Norikazu OTAKE, Takashi HASHIHAYATA, Yohei MATSUDA, Seiji MASUDA, Yuko YAMAUCHI
-
Publication number: 20180282252Abstract: A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 29, 2016Publication date: October 4, 2018Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Norikazu OTAKE, Daisuke MATSUDA, Rie SHIMONO, Hideaki TABUSE, Minoru MORIYA, Yohei KOBASHI, Yohei MATSUDA, Tomokazu TAMAOKI
-
Patent number: 9428483Abstract: Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 31, 2013Date of Patent: August 30, 2016Assignee: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
-
Publication number: 20150141669Abstract: Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 31, 2013Publication date: May 21, 2015Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Takashi Hashihayata, Norikazu Otake, Naoki Miyakoshi, Kazunari Sakagami
-
Patent number: 8846700Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).Type: GrantFiled: September 9, 2013Date of Patent: September 30, 2014Assignee: MSD K.K.Inventors: Tomoharu Iino, Akio Ohno, Norikazu Otake, Takuya Suga, Masanori Asai
-
Publication number: 20140011801Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).Type: ApplicationFiled: September 9, 2013Publication date: January 9, 2014Applicant: MSD K.K.Inventors: Tomoharu Iino, Aklo Ohno, Norikazu Otake, Takuya Suga, Masanori Asai
-
Publication number: 20120270856Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).Type: ApplicationFiled: July 2, 2012Publication date: October 25, 2012Inventors: Tomoharu IINO, Akio OHNO, Norikazu OTAKE, Takuya SUGA, Masanori ASAI
-
Patent number: 8232284Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).Type: GrantFiled: November 10, 2008Date of Patent: July 31, 2012Assignee: MSD K. K.Inventors: Tomoharu Iino, Akio Ohno, Norikazu Otake, Takuya Suga, Masanori Asai
-
Patent number: 7875633Abstract: A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH?CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.Type: GrantFiled: August 23, 2006Date of Patent: January 25, 2011Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Akira Naya, Toshihiro Sakamoto, Yuji Haga, Norikazu Otake
-
Publication number: 20100249146Abstract: Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; R1 represents a group of a formula: (wherein R11 and R12 each independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.; R2 represents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).Type: ApplicationFiled: November 10, 2008Publication date: September 30, 2010Inventors: Tomoharu Iino, Akio Ohno, Norikazu Otake, Takuya Suga, Masanori Asia
-
Patent number: 7803807Abstract: The present invention relates to compounds of Formula (I) wherein A, B and C are independently methine, said methine being optionally substituted; D is nitrogen; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted and least two of T, U, V and W are said methine groups; X is —N(SO2R4)—, N(COR5)— or —CO—; Y is C(R6)(R7)—, —O— or —N(R8) and a pharmaceutically acceptable salt, ester or N-oxide derivative thereof.Type: GrantFiled: October 26, 2009Date of Patent: September 28, 2010Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Otake, Minoru Moriya, Yoshio Ogino, Kenji Matsuda, Yoshikazu Nagae, Akio Kanatani, Takehiro Fukami
-
Publication number: 20100216758Abstract: An active ingredient is a compound represented by the general formula [I]: [wherein R1 and R2 represent a lower alkyl group, a C3-6 cycloalkyl group or the like, X1 and X2 represent methine, an Ar—Y1—Y2—Y3-substituted methine or the like, however either of them is an Ar—Y1—Y2—Y3-substituted methine, X3 to X8 represent methine, —N— or the like, Y1 and Y3 represent a single bond, —O— or the like, Y2 represent a single bond, a lower alkylene group or the like, W represent —(O)—(CH2)n-(O)— or the like, n represents an integer of 1 to 4, L and Z2 represent a single bond or a methylene group, Z1 represents a single bond, a C1-4 alkylene group or the like, and Ar represents an aromatic carbocyclic group or the like]. The compound acts as a melanin-concentrating hormone receptor antagonist and useful as a therapeutic agent for obesity or the like.Type: ApplicationFiled: August 3, 2006Publication date: August 26, 2010Inventors: Makoto Ando, Etsuko Sekino, Yuji Haga, Norikazu Otake, Minoru Moriya
-
Patent number: 7732456Abstract: The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R1 and R2 may be same or different and stands for H, etc., or R1 and R2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X1-X3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X4-X7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y1 and Y3 may be same or different and stand for single bond, —O—, —NR—, —S—, etc; Y2 stands for lower lkylene, etc.; R stands for H, etc., L stands for methylene; Z1 and Z2 may be same or different and stand for single bond or lower alkylene; or R1, L and Z2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R1 binds; and Ar stands for aromatic carbocyclic group, etc.].Type: GrantFiled: March 4, 2005Date of Patent: June 8, 2010Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Otake, Yuji Haga, Akira Naya, Sayaka Mizutani, Akio Kanatani